戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 s into draining lymph nodes (LNs) 24 h after epicutaneous administration of FITC in naive mice was si
2 immunization with Alum-adsorbed rBet v 1 and epicutaneous administration of rBet v 1 with PDS in comb
3   Inhibition of Met signaling by single-dose epicutaneous administration of the Met kinase-specific i
4                                              Epicutaneous allergen administration using a patch may b
5 dies have uncovered a skin-gut axis in which epicutaneous allergen exposure drives intestinal mast ce
6 cal application of MC903, and (2) induced by epicutaneous allergen ovalbumin (OVA) sensitization.
7 omal lymphopoietin, an alarmin implicated in epicutaneous allergen sensitization.
8 ll versus wild-type BALB/c mice following an epicutaneous allergen-sensitization/challenge model that
9                                    Recently, epicutaneous allergen-specific immunotherapy (EPIT) has
10                                              Epicutaneous allergen-specific immunotherapy (EPIT) is p
11            The results of our third trial on epicutaneous allergen-specific immunotherapy (EPIT) will
12                                              Epicutaneous allergen-specific immunotherapy (EPIT) with
13 o explore the potential of laser-facilitated epicutaneous allergen-specific treatment.
14 iated with reduced pathogen loads, in murine epicutaneous and intradermal S. aureus inoculation model
15 reduces skin colonization in mouse models of epicutaneous and systemic infection.
16 "effects," "label," "de-labeling," "prick or epicutaneous," and "intradermal" skin testing, "oral cha
17 f (1) an intact epidermal barrier to prevent epicutaneous antigen presentation, (2) the presence of s
18 enetically engineered mice were subjected to epicutaneous antigen sensitization and the development o
19 ng ovalbumin or Aspergillus fumigatus as the epicutaneous antigen.
20 hance the skin's adaptive immune response to epicutaneous antigens.
21 and the associated lymphoid tissue following epicutaneous application and intracutaneous injection of
22         This defect was tissue-specific, and epicutaneous application of antigen generated a populati
23 sing an AD mouse model, we demonstrated that epicutaneous application of antigen together with supera
24 les were collected 6, 24, and 48 hours after epicutaneous application of Dermatophagoides farinae hou
25                                              Epicutaneous application of dinitrothiocyanobenzene (DNT
26 ation into humans was also accomplished with epicutaneous application of fingolimod resolving histami
27                                              Epicutaneous application of labeled allergen allowed for
28      Notably, both intradermal injection and epicutaneous application of lauric acid effectively decr
29  sebaceous glands of mouse ear skin after an epicutaneous application of OA, the most hBD-2-inducible
30 DCs in the generation of immune responses to epicutaneous application of ovalbumin and during contact
31        Mice epidermal barrier was damaged by epicutaneous application of proteases and cholera toxin
32                                              Epicutaneous application of protein antigen in the prese
33 zed into three groups: (1) models induced by epicutaneous application of sensitizers; (2) transgenic
34 sensitivity responses induced in mice by the epicutaneous application of the haptens FITC and oxazolo
35 eradicated by a simple vaccination strategy: epicutaneous application of the related orthopoxvirus va
36  described an animal model in which repeated epicutaneous applications of a house dust mite extract a
37 o a physiological skin self-Ag desmoglein-3, epicutaneous applications of desmoglein-3 induced tolera
38 herapy, none are currently approved, but the epicutaneous approach is the most well-studied and other
39 ice exhibited an exaggerated Th2 response to epicutaneous but not to intraperitoneal sensitization wi
40  responsible for protective immunity against epicutaneous Candida infections are incompletely charact
41                         We infected mice via epicutaneous challenge of the skin on the outer ear pinn
42 d as an increase in ear thickness 24 h after epicutaneous challenge, was significantly enhanced in ma
43              The study of nanotechnology for epicutaneous delivery of pharmaceuticals and vaccines is
44                                   Mucosal or epicutaneous delivery of vaccines helps target the induc
45 ontrast, IL-4(-/-) mice initially exposed to epicutaneous (e.c.) OVA mounted Th2 responses equivalent
46 ination of intense pruritus, scratching, and epicutaneous (e.c.) sensitization with allergens.
47    Allergic skin inflammation in response to epicutaneous (EC) application of ovalbumin to tape-strip
48                                              Epicutaneous (EC) immunization of mice with ovalbumin (O
49        Herein, we describe a murine model of epicutaneous (EC) sensitization to the protein allergen,
50 lergic skin inflammation elicited in mice by epicutaneous (EC) sensitization with antigen shares char
51 ouse model of allergic dermatitis induced by epicutaneous (EC) sensitization with OVA on tape-strippe
52  in a preclinical mouse model that S. aureus epicutaneous exposure induced eosinophil-recruiting chem
53 reviously unknown pathway by which S. aureus epicutaneous exposure promotes skin inflammation involvi
54 ese findings provide the first evidence that epicutaneous exposure to allergens potently primes for E
55         We aimed to test the hypothesis that epicutaneous exposure to antigen primes for subsequent r
56 d protein in human skin biopsy samples after epicutaneous exposure to liquid-phase HDI, although the
57  have reported that Th2 responses induced by epicutaneous exposure to OVA are IL-4 independent.
58                     Further, after 7 days of epicutaneous exposure to wild-type S. aureus, but not S.
59 skin allergen sensitization during S. aureus epicutaneous exposure-induced IL-36 responses was requir
60 ependent cellular immune response induced by epicutaneous hapten.
61                                              Epicutaneous HDM application led to TH2 sensitization an
62                            We show here that epicutaneous immunization (ECi) with the immunodominant
63                         BALB/c mice received epicutaneous immunization (EPI) with recombinant Bet v 1
64       Allergic skin inflammation elicited by epicutaneous immunization of mice with ovalbumin (OVA),
65                                              Epicutaneous immunization of T cell receptor (TCR) trans
66                 The study also suggests that epicutaneous immunization or immunotherapy can be improv
67 spare other Langerin(+) DC do not impair the epicutaneous immunization response to OVA.
68                                              Epicutaneous immunization was performed by applying a sk
69                                              Epicutaneous immunization with CT does not require engag
70            Finally, the results suggest that epicutaneous immunization with OVA and CpG decreases the
71                                              Epicutaneous immunization with OVA and CpG reduces the p
72 C elimination reduced the T cell response to epicutaneous immunization with OVA protein Ag.
73 s as well as IL-10 cytokine production after epicutaneous immunization with ovalbumin (OVA).
74                                              Epicutaneous immunization with rBet v 1 plus R848 induce
75 g-specific CD4 and CD8 T cell responses upon epicutaneous immunization, but could not detect a role i
76  antigen delivery through the unbroken skin (epicutaneous immunization, EPI) has immediate relevance
77 ize the regulatory cells that are induced by epicutaneous immunization.
78                          We evaluated peanut epicutaneous immunotherapy (EPIT) by using Viaskin Peanu
79 o children with peanut allergy engaged in an epicutaneous immunotherapy (EPIT) clinical trial.
80 igation of sublingual/oral immunotherapy and epicutaneous immunotherapy (EPIT) currently in the clini
81 nsitized piglets to evaluate the efficacy of epicutaneous immunotherapy (EPIT) for its treatment.
82 eviously reported the safety and efficacy of epicutaneous immunotherapy (EPIT) for peanut allergy (25
83 ent modalities, oral immunotherapy (OIT) and epicutaneous immunotherapy (EPIT) have been the best stu
84 ficacy and mechanism of tolerance induced by epicutaneous immunotherapy (EPIT) in a model of food-ind
85                                              Epicutaneous immunotherapy (EPIT) is a promising method
86 se III study results suggest investigational epicutaneous immunotherapy (EPIT) may be a relevant and
87    We sought to evaluate the effect of early epicutaneous immunotherapy (EPIT) on further sensitizati
88                                              Epicutaneous immunotherapy (EPIT) protocols have recentl
89 of this study was to compare the efficacy of epicutaneous immunotherapy (EPIT) to sublingual immunoth
90                                              Epicutaneous immunotherapy (EPIT) was performed using fr
91 ovel approaches are being studied, including epicutaneous immunotherapy (EPIT).
92                       The response to peanut epicutaneous immunotherapy (Peanut Epicutaneous Phase II
93 tein were assigned in a 2:1 ratio to receive epicutaneous immunotherapy delivered by means of a peanu
94 ren 1 to 3 years of age with peanut allergy, epicutaneous immunotherapy for 12 months was superior to
95        R848 could be a promising adjuvant in epicutaneous immunotherapy for birch pollen-induced alle
96 therapeutic trials were established to study epicutaneous immunotherapy for peanut allergy and to com
97                                              Epicutaneous immunotherapy increased tolerance whilst on
98                                              Epicutaneous immunotherapy is safe and efficacious in a
99                                              Epicutaneous immunotherapy may have potential for treati
100 e Food and Drug Administration, and a peanut epicutaneous immunotherapy patch was under review.
101 e treatment of peanut-allergic children with epicutaneous immunotherapy remains to be determined.
102   Recently, the safety and early efficacy of epicutaneous immunotherapy were also demonstrated in pat
103 andomized clinical trial, 12 months of daily epicutaneous immunotherapy with a dose of Viaskin milk a
104 years of age, and the efficacy and safety of epicutaneous immunotherapy with a peanut patch in toddle
105 t, and R848 (resiquimod), a TLR7 agonist, in epicutaneous immunotherapy with Bet v 1, the major birch
106                                              Epicutaneous immunotherapy with investigational Viaskin(
107 al Trial [CoFAR6]; 49 participants receiving epicutaneous immunotherapy) and egg oral immunotherapy o
108 50 participants (total = 130 weeks of active epicutaneous immunotherapy).
109 50 participants (total = 130 weeks of active epicutaneous immunotherapy).
110               Studies of oral immunotherapy, epicutaneous immunotherapy, and SLIT have suggested addi
111 ical trials, including oral, sublingual, and epicutaneous immunotherapy, immunotherapy combined with
112 from a randomized controlled trial of peanut epicutaneous immunotherapy, observing modest and statist
113 n appear to be necessary for the response to epicutaneous immunotherapy.
114 ublingual immunotherapy, and, more recently, epicutaneous immunotherapy.
115 or forms of treatment: oral, sublingual, and epicutaneous immunotherapy.
116 ameters following extended open-label peanut epicutaneous immunotherapy.
117                               Using a murine epicutaneous infection model, we found that S. aureus-ex
118 dels, (iii) wound infection models, and (iv) epicutaneous infection models.
119          Previously, we developed a model of epicutaneous infection with Microsporum canis in C57BL/6
120  CD4 and CD8 T cells after needle injection, epicutaneous infection, or vaginal mucosal herpes simple
121  cells after vaginal infection compared with epicutaneous infection.
122 , we tested whether vaccinating mice with an epicutaneous influenza patch containing TJ-disrupting pe
123 y protects mouse skin from S. aureus-induced epicutaneous injury, as evidenced by reduced bacterial b
124 n immunotherapy have been studied, including epicutaneous, intralymphatic, intranasal, and oral immun
125 IT (SLIT) had a RR of 3.00 [1.04, 8.66], and epicutaneous IT (EPIT) of 2.16 [1.56, 3.00].
126 ization of mice by subcutaneous injection or epicutaneous laser microporation induced comparable IgG
127 monella typhimurium and perish shortly after epicutaneous or orogastric infection respectively.
128 d allergies; these involve oral, sublingual, epicutaneous, or subcutaneous administration of small am
129 study, we show that Th2 responses induced by epicutaneous OVA exposure (including lung inflammatory r
130                                     However, epicutaneous OVA sensitization occurred in OVA patched m
131 iased allergic skin inflammation elicited by epicutaneous ovalbumin (OVA) sensitization exhibited lar
132 atricians and perhaps more widespread use of epicutaneous patch testing.
133 ration for improving the effectiveness of an epicutaneous patch-based vaccine, without adversely affe
134                                In mice, this epicutaneous peanut exposure induced sensitization to th
135 omly assigned patients (1:1:1:1) received an epicutaneous peanut patch containing 50 mug (n = 53), 10
136 py (EPIT) for peanut allergy (250 mug, daily epicutaneous peanut protein; DBV712 250 mug).
137 he specific antibody response induced by our epicutaneous Pertussis vaccine candidate containing non-
138 to peanut epicutaneous immunotherapy (Peanut Epicutaneous Phase II Immunotherapy Clinical Trial [CoFA
139                 These were then tested in an epicutaneous protein (ovalbumin, Ova) sensitization mode
140 esponse to both contact hypersensitivity and epicutaneous protein immunization, and resulted in a dra
141 , while enhancing Th2 and Tr1 responses upon epicutaneous protein sensitization.
142     We show that exposure to antigen via the epicutaneous route primes for marked eosinophilic inflam
143                                      Herein, epicutaneous S. aureus exposure to mouse skin promoted M
144 IL-17-mediated skin inflammatory response to epicutaneous S. aureus infection.
145  signaling blockade were used to investigate epicutaneous sensitization and disease progression; we a
146 opoietin (TSLP) have both been implicated in epicutaneous sensitization and food allergy, albeit in d
147 s and human data that support the concept of epicutaneous sensitization and how this forms one half o
148 female mice with ovalbumin (OVA) followed by epicutaneous sensitization and oral challenge of their o
149 vant-free model of food allergy generated by epicutaneous sensitization and reactions triggered by or
150 ulation, and promotes oral anaphylaxis after epicutaneous sensitization by targeting MCs.
151                                              Epicutaneous sensitization caused microscopic skin damag
152                                              Epicutaneous sensitization in mice results in T(H)2-domi
153                                           An epicutaneous sensitization model was used and bone marro
154                                           An epicutaneous sensitization model was used and bone marro
155                                        In an epicutaneous sensitization model, the response to recomb
156         Allergic skin inflammation following epicutaneous sensitization of mice 1 or 2 IL-4Ralpha R57
157                                    Following epicutaneous sensitization of mice with ovalbumin or hou
158 +) B-cell immunity against food allergens in epicutaneous sensitization precedes the generation of Ig
159                                              Epicutaneous sensitization preferentially elicited an IL
160                                              Epicutaneous sensitization promotes generation of antige
161                                              Epicutaneous sensitization results in increased serum le
162 FlgHrnr(-/-) mouse model nicely reflects the epicutaneous sensitization susceptibilities and inflamma
163 mutations (Flakey Tail, FT+/- mice), topical epicutaneous sensitization to a food allergen peanut ext
164                                              Epicutaneous sensitization to food allergen and developm
165 rrier integrity and may increase the risk of epicutaneous sensitization to food allergens.
166 of allergen-specific B-cell responses during epicutaneous sensitization to foods.
167 ersa TLR4 expression rather protects against epicutaneous sensitization to house dust mite allergen D
168                                              Epicutaneous sensitization was found to be driven by 2 v
169  tested in a murine model of EoE elicited by epicutaneous sensitization with Aspergillus fumigatus pr
170 ith filaggrin and mattrin gene mutations) by epicutaneous sensitization with co-exposures to the food
171        We sought to test the hypothesis that epicutaneous sensitization with food antigen predisposes
172 DC in response to various stimuli, including epicutaneous sensitization with hapten and skin infectio
173 se model of allergic inflammation induced by epicutaneous sensitization with OVA.
174 d increased allergic skin inflammation after epicutaneous sensitization with OVA.
175 tly described murine model of AD elicited by epicutaneous sensitization with ovalbumin (OVA) (1) and
176 ic skin inflammation was elicited in mice by epicutaneous sensitization with ovalbumin (OVA) or cutan
177 lergic skin inflammation induced by repeated epicutaneous sensitization with ovalbumin (OVA), and cha
178 gal3(-/-)) and wild-type (gal3(+/+)) mice to epicutaneous sensitization with ovalbumin (OVA).
179                                              Epicutaneous sensitization with ovalbumin of WT mice but
180                                              Epicutaneous sensitization- and bone marrow reconstituti
181 amage and infection, during steady-state and epicutaneous sensitization.
182 and anaphylaxis that involved either oral or epicutaneous sensitization.
183 cretion of Th2 cytokines by splenocytes from epicutaneous sensitized TSLPR(-/-) mice in response to O
184 d skin thickening and collagen deposition in epicutaneous-sensitized skin of DeltadblGATA recipients.
185 ALB/cJ control mice were exposed to 3 weekly epicutaneous skin patches of one of saline, ovalbumin (O
186                              Moreover, after epicutaneous Staphylococcus aureus application, impaired
187 dermatitis-like skin inflammation induced by epicutaneous Staphylococcus aureus exposure, keratinocyt
188  Liu et al. (2017) define a pathway by which epicutaneous Staphylococcus aureus promotes skin inflamm
189 re the allergen are not found by history and epicutaneous testing is required.
190                  Skin prick, intradermal and epicutaneous tests, in vitro sIgE assessment, evaluation
191 ct, and identifies novel mechanisms by which epicutaneous tolerance can suppress food-induced anaphyl
192                                              Epicutaneous treatment of sensitized animals led to indu
193               We sought to determine whether epicutaneous treatment with antigen in the presence of a
194                                              Epicutaneous treatment with vinblastine caused a reducti
195  method for potentiating the efficacy of our epicutaneous vaccination approach using a minimally inva
196                                              Epicutaneous vaccination has gained increasing interest
197                       One major challenge to epicutaneous vaccination is the barrier function of the
198 s human and murine skin epithelium, enabling epicutaneous vaccine delivery.
199 vaccination method without adjuvant based on epicutaneous vaccine patches on which antigen forms a dr
200 n C fragment when administered as a nasal or epicutaneous vaccine.
201 ractions with virus-infected cells following epicutaneous vaccinia virus (VV) infection of mice.
202                                              Epicutaneous vaccinia virus (VV) infection, mimicking hu
203 g chemokines, which accelerates clearance of epicutaneous vaccinia virus infection.

 
Page Top